ICER says 'marginal' benefits for AbbVie's new RA drug

AbbVie’s Rinvoq rheumatoid arthritis drug is an important part of the company’s strategy to replace lost sales as its mega-blockbuster Humira finally succumbs to cheaper biosimilar competit

FDA nod for AZ’s Calquence sets up new Imbruvica showdown

AbbVie signs potential $2.4bn cancer immunotherapy deal with...

AbbVie has signed a deal worth up to $2.4 billion with the US biotech Harpoon Therapeutics, expanding a research and licensing collaboration involving technology that trains T-cells to targ

FDA approves latest Humira near-copy, as dozens of biosimila...

The FDA has approved Pfizer’s biosimilar of AbbVie’s blockbuster Humira (adalimumab), meaning that there are now five of these cheaper near-copies teed up to compete when the originator’s p

Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthrit...

Reata rockets on data for Nrf2 drug reacquired from AbbVie